Avalo Therapeutics (NASDAQ:AVTX) Trading 6.2% Higher – Still a Buy?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was up 6.2% during mid-day trading on Friday . The company traded as high as $18.95 and last traded at $18.9850. 517,899 shares were traded during trading, a decline of 58% from the average daily volume of 1,233,941 shares. The stock had previously closed at $17.88.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AVTX. Leerink Partners started coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Piper Sandler restated an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Bank of America initiated coverage on Avalo Therapeutics in a research note on Friday, June 12th. They set a “buy” rating and a $35.00 price objective on the stock. Citizens Jmp cut their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $45.80.

Avalo Therapeutics Stock Up 5.3%

The stock has a 50-day moving average of $16.89 and a 200 day moving average of $16.08. The company has a market capitalization of $989.42 million, a PE ratio of -3.46 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. Equities analysts forecast that Avalo Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.

Insider Transactions at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,428 shares of company stock worth $1,762,722 in the last ninety days. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG raised its holdings in shares of Avalo Therapeutics by 956.9% in the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after purchasing an additional 432,608 shares during the period. Moody Aldrich Partners LLC bought a new position in Avalo Therapeutics during the fourth quarter valued at $2,419,000. Nan Fung Trinity HK Ltd. purchased a new stake in Avalo Therapeutics in the fourth quarter worth $3,432,000. Cantor Fitzgerald L. P. bought a new stake in shares of Avalo Therapeutics in the third quarter valued at $1,083,000. Finally, Jennison Associates LLC bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at $8,637,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.